Local therapy of cancer with free IL-2 by Den Otter, Willem et al.




Local therapy of cancer with free IL-2
Willem Den Otter · John J. L. Jacobs · Jan J. Battermann · Gerrit Jan Hordijk · 
Zachary Krastev · Ekaterina V. Moiseeva · Rachel J. E. Stewart · 
Paul G. P. M. Ziekman · Jan Willem Koten 
Received: 31 August 2007 / Accepted: 14 January 2008 / Published online: 7 February 2008
© The Author(s) 2008
Abstract This is a position paper about the therapeutic
eVects of locally applied free IL-2 in the treatment of cancer.
Local therapy: IL-2 therapy of cancer was originally intro-
duced as a systemic therapy. This therapy led to about 20%
objective responses. Systemic therapy however was very
toxic due to the vascular leakage syndrome. Nevertheless,
this treatment was a break-through in cancer immunother-
apy and stimulated some interesting questions: Supposing
that the mechanism of IL-2 treatment is both proliferation
and tumoricidal activity of the tumor inWltrating cells, then
locally applied IL-2 should result in a much higher local
IL-2 concentration than systemic IL-2 application. Con-
sequently a greater beneWcial eVect could be expected
after local IL-2 application (peritumoral = juxtatumoral,
intratumoral, intra-arterial, intracavitary, or intratracheal =
inhalation). Free IL-2: Many groups have tried to prepare a
more eVective IL-2 formulation than free IL-2. Examples
are slow release systems, insertion of the IL-2 gene into a
tumor cell causing prolonged IL-2 release. However, logisti-
cally free IL-2 is much easier to apply; hence we concen-
trated in this review and in most of our experiments on the
use of free IL-2. Local therapy with free IL-2 may be eVec-
tive against transplanted tumors in experimental animals,
and against various spontaneous carcinomas, sarcomas, and
melanoma in veterinary and human cancer patients. It may
induce rejection of very large, metastasized tumor loads, for
instance advanced clinical tumors. The eVects of even a
single IL-2 application may be impressive. Not each tumor
or tumor type is sensitive to local IL-2 application. For
instance transplanted EL4 lymphoma or TLX9 lymphoma
were not sensitive in our hands. Also the extent of sensitiv-
ity diVers: In Bovine Ocular Squamous Cell Carcinoma
(BOSCC) often a complete regression is obtained, whereas
with the Bovine Vulval Papilloma and Carcinoma Complex
(BVPCC) mainly stable disease is attained. Analysis of the
results of local IL-2 therapy in 288 cases of cancer in
human patients shows that there were 27% Complete
Regressions (CR), 23% Partial Regressions (PR), 18% Sta-
ble Disease (SD), and 32% Progressive Disease (PD). In all
tumors analyzed, local IL-2 therapy was more eVective than
systemic IL-2 treatment. Intratumoral IL-2 applications are
more eVective than peritumoral application or application
at a distant site. Tumor regression induced by intratumoral
IL-2 application may be a fast process (requiring about a
week) in the case of a highly vascular tumor since IL-2
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induces vascular leakage/edema and consequently massive
tumor necrosis. The latter then stimulates an immune
response. In less vascular tumors or less vascular tumor
sites, regression may require 9–20 months; this regression is
mainly caused by a cytotoxic leukocyte reaction. Hence the
disadvantageous vascular leakage syndrome complicating
systemic treatment is however advantageous in local treat-
ment, since local edema may initiate tumor necrosis. Thus
the therapeutic eVect of local IL-2 treatment is not primarily
based on tumor immunity, but tumor immunity seems to be
useful as a secondary component of the IL-2 induced local
processes. If local IL-2 is combined with surgery, radiother-
apy or local chemotherapy the therapeutic eVect is usually
greater than with either therapy alone. Hence local free IL-2
application can be recommended as an addition to standard
treatment protocols. Local treatment with free IL-2 is
straightforward and can readily be applied even during sur-
gical interventions. Local IL-2 treatment is usually without
serious side eVects and besides minor complaints it is gener-
ally well supported. Only small quantities of IL-2 are
required. Hence the therapy is relatively cheap. A single IL-
2 application of 4.5 million U IL-2 costs about 70 Euros.
Thus combined local treatment may oVer an alternative in
those circumstances when more expensive forms of treat-
ment are not available, for instance in resource poor coun-
tries.
Keywords Interleukin-2 · Immunotherapy · BOSCC · 
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Systemic IL-2 therapy of cancer
Rosenberg and co-workers were the Wrst to treat cancer
with IL-2. They showed that IL-2 renders white blood cells
cytotoxic in vitro. These cells were coined Lymphokine
Activated Killer cells (LAK cells). Rosenberg and co-work-
ers treated transplanted lung metastases in mice. Injection
of IL-2 plus LAK cells clearly reduced the number of
metastases in the lung [82]. Next these authors treated 25
consecutive patients with diVerent types of advanced can-
cer for whom no eVective treatment was available. In 11
patients, objective responses were obtained after treatment
with IL-2 and LAK cells [81]. Obviously this paper
attracted worldwide attention, as it was a breakthrough in
immunological treatment of cancer. In further studies, sys-
temic application of IL-2 with or without LAK cells
appeared useful in patients with metastasized renal cell car-
cinoma and metastasized melanoma. In both conditions
about 20% objective responses were obtained; that is about
6% complete and about 14% partial tumor regressions [57].
Repeated cycles of systemic IL-2 administration were
required to achieve systemic tumor-inhibitory eVects.
Grande et al. [46] recently reviewed the therapeutic eVects
of systemic IL-2 therapy.
Systemic IL-2 application required bolus injections of
IL-2 given every 8 h at a dose of 105 IU/kg body weight for
at least 5 days. These high doses were very toxic, as sys-
temic IL-2 therapy induces a generalized vascular leakage
syndrome [7, 83]. In addition the preparation and applica-
tion of LAK cells was cumbersome indeed. Supposing that
the tumor inWltrating leucocytes have to be stimulated by
IL-2, we and other groups decided to focus on local IL-2
therapy, that is IL-2 application at the site of the tumor
(peritumoral = juxtatumoral, intratumoral, intra-arterial,
intracavitary infusion, or inhalation). Since local IL-2
application requires smaller doses of IL-2 than systemic
treatment, less complications were expected. Locally
applied relatively small doses of IL-2 leads to much higher
IL-2 concentrations at the site of the tumor and to much
lower concentrations elsewhere in the body.
Conclusion
The development of systemic IL-2 therapy was a break-
through in cancer immunotherapy. We supposed that the
drawbacks of systemic IL-2 application might be overcome
by local IL-2 application.
EVectiveness of local versus systemic IL-2 therapy
Subject
The therapeutic eVectiveness of local versus systemic IL-2
application.
Data
Silagi et al. [86] studied mice with melanoma or sarcoma
using combined cyclosphosphamide and IL-2. Cyclophos-
phamide was always applied systemically. Cyclophospha-
mide alone had no therapeutic eVect but combined
treatment of cyclophosphamide and IL-2 showed a syner-
gistic eVect. When either tumor was implanted s.c. at day 0,
and IL-2 treatment was given at the site of the tumor begin-
ning 1–3 days later, 87–100% of the mice were cured. Only
35–50% were cured when IL-2 was administered i.p. Con-
versely, with i.p. treatment of i.p. tumors, 60–83% of the
mice were tumor-free on day 50, as compared with only
17% with s.c.treatment.
Vaage [94] tested the therapeutic eVects of 12 daily
injections of 100–300,000 U of human IL-2 against the
syngeneic, immunogenic mammary carcinoma MC2
implanted s.c. into C3H/He mice. A local therapeutic eVect
was observed after injecting tumors even with doses as lowCancer Immunol Immunother (2008) 57:931–950 933
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as 300 U of IL-2 per injection. Systemic IL-2 treatment
however required at least 5,000 U per injection for obtain-
ing discernable results.
Belardelli et al. [10] treated mice with s.c. transplanted
highly metastatic Friend leukemia, non-metastatic Friend
leukemia, RBL-5 lymphoma, and HeJ16 Wbrosarcoma. In
all these tumor models, peritumoral injections of IL-2 were
more eVective in inhibiting tumor growth than systemic
treatment.
Anderson et al. [2] studied the therapeutic eVects of IL-2
in C57BL/6 mice with MCA-106 sarcoma pulmonary
metastases. When mice were treated once daily with free
IL-2 on days 5, 6, and 7 after tumor inoculation, the intra-
thoracic route was superior to the i.p. or s.c. routes.
Maas et al. [68] treated DBA/2 mice bearing i.p. and s.c.
SL2 lymphoma. If IL-2 was injected i.p., then in 70% of the
mice i.p. tumors regressed completely, and in 50% tumors
regressed completely both i.p. and s.c. When mice had only
a s.c. growing tumor and IL-2 was injected i.p., then in only
7% of the mice tumors regressed completely.
Dubinett et al. [33] transplanted s.c. Line 1 alveolar car-
cinoma cells in Balb/c mice. On the third day following
tumor implantation, mice received injections of IL-2 twice
daily, either by i.p. or intratumoral injection, 5 days/week
for 3 weeks. Intratumoral injection of IL-2 signiWcantly
reduced the tumor volume, increased the median survival
time, and resulted in a 23.5% cure rate. However no long-
term survivors were among the i.p. treated mice.
Jacobs et al. [55] investigated human patients with naso-
pharyngeal carcinoma. Local IL-2 treatment was combined
with standard irradiation therapy. Sixty three % of the
patients showed a disease free survival during the next
5 years, whereas only 8% of the controls treated with irradi-
ation alone were still disease free after 5 years. Interest-
ingly, these results contrast with those of Chi et al. [23]
who applied single modality systemic IL-2 therapy. They
concluded that no response was observed. So, apparently,
local IL-2 application is more eVective than systemic appli-
cation. It is important that these results of Jacobs et al. and
Chi et al. were obtained in spontaneously occurring tumors,
not with transplanted tumors.
Local IL-2 should even preferably be given intratumor-
ally as IL-2 application adjacent to the tumor is far less
eVective. Jacobs et al. [56] compared the eVect of peritu-
moral and intratumoral IL-2 therapy in mice with s.c. trans-
planted SL2 lymphoma. Intratumoral IL-2 was signiWcantly
more eVective than peritumoral IL-2. Krastev et al. [61]
treated 16 patients with various gastrointestinal tumors
with intratumoral and/or intraperitoneal IL-2 therapy. Six
patients had a clinical response. All six belonged to the
group of seven patients who received intratumoral therapy.
No objective responses were obtained in patients treated
only with intraperitoneal IL-2.
In an early review Bernsen et al. already concluded that
locoregional IL-2 treatment was more eVective than sys-
temic treatment [13]. Since then an overwhelming amount
of research has corroborated this conclusion.
Conclusion
The data show that local IL-2 therapy and in particular
intratumoral IL-2 application is more eVective than sys-
temic IL-2 therapy.
Local IL-2 therapy leads to systemic therapeutic 
eVects even curing metastatic disease
Subject
Obviously a major problem of cancer therapy is inducing
regression of metastases. Immunotherapy of cancer is an
attractive concept, as systemic immunity may indeed cure
metastases. Consequently, many groups have concentrated
on the systemic therapeutic eVects of local IL-2 therapy.
Data
Maas et al. [67] have shown that i.p. injections of IL-2 can
cure DBA/2 mice with a large burden of i.p. transplanted
and greatly disseminated SL2 lymphoma. This implied
that tumor metastases can be successfully treated with
local IL-2 therapy. In more detailed studies SL2 tumor
cells were injected in mice both i.p. and s.c. on the Xank
resulting in i.p. and s.c. tumors [67]. About 50% of the
mice treated i.p with IL-2 rejected both the i.p. tumor and
the large distant s.c. tumor. In contrast, similar i.p. treat-
ment cured only 7% of the mice bearing only a s.c. SL2
tumor. Thus, it was shown that IL-2 can induce systemic
tumor rejection when injected at the site of tumor growth.
This SL2 tumor rejection was speciWc, as mice that were
rejecting i.p. and s.c. SL2 lymphoma did not reject P815
mastocytoma.
Vaage [95] tested the therapeutic eVects of IL-2 against
intramammary implants of an immunogenic, syngeneic
C3H mammary carcinoma. Peritumoral injected IL-2 had
almost equal local and systemic therapeutic eVects, whereas
systemically injected IL-2 was not therapeutically eVective
at all.
Immunity also explains the long lasting absence
(>54 months) of bladder carcinoma recurrences in two IL-2
treated patients who previously had a 7 and 11 years’ his-
tory of recurrent bladder cancer [29].
Van Es et al. [96] showed that peritumoral injections
of IL-2 in a transplanted rabbit carcinoma model can
induce complete regression of the treated tumors as well934 Cancer Immunol Immunother (2008) 57:931–950
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as untreated contralateral tumors in four out of 12 rab-
bits. Also metastases in the draining regional lymph
nodes of both treated and untreated primary tumors
regressed in three of these animals. So, local treatment of
a tumor led to systemic eVects curing untreated tumors at
a distant site as well as metastases in the draining lymph
nodes of both the treated and the untreated tumors. A sec-
ond challenge with tumor cells of the cured animals was
rejected.
Jacobs et al. [56] transplanted in mice tumors at two
diVerent sites. Rejection of the intratumoral IL-2 treated
tumors was stronger than rejection of the untreated tumors.
Systemic immunity is also likely in patients with naso-
pharyngeal carcinoma treated with radiotherapy and intra-
tumoral IL-2 application [55]. Addition of IL-2 to the
standard radiotherapy reduced the number of loco regional
and distant recurrences.
In line with these observations is the Wnding that local or
generalized eVector dysfunction of the immune system can
be reversed by IL-2 exposure in patients with advanced
cancer [70].
Conclusion
Local IL-2 therapy can also cause systemic therapeutic
eVects, probably due to immune reactivity [68, 96].
Therapeutic eVects of local IL-2 therapy against 
transplanted tumors in laboratory animals (Tables 1, 2)
Subject
For studying the potential therapeutic eVects of anticancer
drugs one has to start in animal models using transplanted
tumors, as well-performed and well-interpreted studies in
animals have predictive value regarding the therapeutic
eVectiveness of a drug in human cancer patients [32].
Data
As early as in 1983, Bubenik and co-workers [18]
established that peritumoral injections of rat lymphoid
IL-2 suppressed or markedly inhibited the growth of
methylcholanthrene-induced sarcomas in syngeneic mice.
An equally eVective inhibition of murine sarcoma trans-
plants in syngeneic recipients could be obtained with crude
lymphoid rat IL-2, with puriWed IL-2 of murine lymphoid
origin, and with molecularly homogeneous human recom-
binant IL-2 [16–18].
Maas et al. [67] injected DBA/2 mice i.p. with SL2 cells
and 10–14 days later these mice were treated with i.p. IL-2
injections. At the time of IL-2 injection the transplanted
SL2 tumor had greatly expanded by growth, inWltration and
Table 1 Successful therapeutic eVects of local IL-2 application on transplanted tumors: results published by other groups
We have included data of all papers that we have found on therapeutic eVects of local application of free IL-2 to transplanted cancer in animals
A well-recognized problem with a Table like this one is that usually positive results are published, in contrast to negative results. So, there is a
positive publication bias.The message of Table 1 is not that all transplanted tumors are sensitive, but that positive therapeutic eVects have been
obtained in many diVerent models and many diVerent tumor types
+ Clear therapeutic eVect
++ Many cures were obtained






Mammary carcinomas Mouse Peritumoral + [94, 95]
Transitional cell carcinoma Mouse Intratumoral + [87]
Lung carcinoma Mouse Intratumoral ++ [33]
Prostate carcinoma Rat Intratumoral + [50]
Sarcomas
MC-induced sarcomas Mouse Peritumoral + [16–18]
HeJ Wbrosarcoma Mouse Peritumoral ++ [10]
MCA106 sarcoma Mouse Peritumoral + [2]
Lymphoma
RBL5 lymphoma Mouse Peritumoral + [10]
Miscellaneous
Myeloma X5563 Mouse Local site ++ [69]
Melanoma Mouse Tumor site ++ [86]
Friend leukemia Mouse Peritumoral + [10]
HPV associated tumor Mouse Tumor site + [21]Cancer Immunol Immunother (2008) 57:931–950 935
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metastasis. A mouse of 25 gram developed in 10 days a
tumor load of at least 5 g, about 5 £ 109tumor cells. Never-
theless about 25% of these mice were cured by IL-2. This
was a very important step forward in immunotherapy of
cancer. The therapeutic eVects were dose-dependent. These
data were conWrmed in more elaborated studies by Bernsen
et al. [12] and by Everse et al. [37].
Tables 1 and 2 summarize the therapeutic results of local
IL-2 application to transplanted tumors. Table 1 displays the
results obtained by other groups and Table 2 results by our
group. Both Tables show that local IL-2 therapy may be
eVective in a broad range of tumor types such as carcinomas
[6, 33, 42, 50, 58, 64, 72, 73, 87, 94, 96], sarcomas [10, 16–
18, 86], a myeloma [69], lymphomas [10, 66, 67], leukemia
[10], a mastocytoma [68], and HPV associated tumor [21].
Obviously not all cancers are sensitive to IL-2 therapy.
Our group studied the eVect of local IL-2 therapy in 19
models of transplanted tumors (Table 2). In 15 models pos-
itive therapeutic results were obtained. IL-2 applied in
breast cancers was only moderately eVective. In four mod-
els no therapeutic eVects were obtained, namely murine
5D04 stomach carcinoma [27], murine MOT teratoma [14],
murine EL4 lymphoma [27] and murine TLX9 lymphoma
[27]. Why some tumors are sensitive to local IL-2 therapy
and other tumor models do not show any response, remains
hitherto an enigma. The data summarized in Tables 1 and 2
demonstrate that local IL-2 therapy has the capability to
destroy tumor cells and to cure the hosts.
An animal model using transplanted tumors has predic-
tive value for the therapeutic eVect in human cancer if the
model tumor comprises more than 1% of the body weight
of the host and if this tumor is metastasized [32]. Eight
models mentioned in Table 2 fulWl these requirements, viz.
the models marked in column 4 with +. So, the positive
Table 2 Therapeutic eVect of local IL-2 application on transplanted tumors: results from our group
This Table presents all results obtained with models tested by our group; so there is no selection bias (in contrast to Table 1)
§ therapeutic eVects just measurable, + therapeutic eVects are clear; ++ animals can be cured from extensive tumor loads
The four negative models were only tested in a few experiments, until we were convinced that therapeutic eVects were not obtained in our hands.
Three of the four negative models were not published for obvious reasons. On the other hand, SL2 lymphoma in syngeneic DBA/2 mice is our
standard model since the 1989 paper of Maas et al. [68]. Numerous studies were performed with this model. The therapeutic eVect of local IL-2
application was always clear








Line 10 Liver Guinea pig + Intratumoral + [6, 72]
M8013 Breast Mouse Peritumoral + [58]
MOT Teratoma Mouse Intratumoral - [14]
MC-ASN Breast Mouse + Peritumoral § [73]
MC-BC Breast Mouse + Peritumoral § [73]
MC38 Colon Mouse + Peritumoral + [64]
5D04 Stomach Mouse Intratumoral -
VX2 carcinoma Head and Neck Rabbit + Peritumoral + [96]
Recently arisen carcinomas
X5 Breast Mouse Intratumoral § [42]
X6 Breast Mouse Intratumoral § [42]
X9 Breast Mouse Intratumoral § [42]
Sarcoma
Mecho Fibrosarcoma Mouse Intratumoral +
Lymphomas
SL2 Lymphoma Mouse + Intratumoral ++ [12, 67, 68, 70]
L5178Y Lymphoma Mouse Intratumoral ++ [67]
L1210 Lymphoma Mouse Intratumoral +
RBL5 Lymphoma Mouse Intratumoral +
EL4 Lymphoma Mouse Intratumoral ¡
Miscellaneous
TLX9 Thymoma Mouse Intratumoral ¡
P815 Mastocytoma Mouse + Intratumoral ++ [68]936 Cancer Immunol Immunother (2008) 57:931–950
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therapeutic results obtained with these models predict that
local IL-2 therapy can be therapeutically eVective in human
patients with metastatic cancer.
Conclusion
In models with transplanted tumors in laboratory animals
there is overwhelming evidence showing the therapeutic
eVect of local application of free IL-2. This therapy is eVec-
tive against a broad range of tumors. In addition the magni-
tude of the therapeutic data (for instance [67]) suggests that
this form of therapy can also induce objective therapeutic
responses in human cancer patients.
N.B. Not every transplanted tumor or tumor type is sen-
sitive to local IL2 application. For instance transplanted
EL4 lymphoma or TLX9 lymphoma are not sensitive in our
hands (Table 2).
Local IL-2 tumor treatment in veterinary patients 
(Table 3)
Subject
Positive results in veterinary patients with spontaneous can-
cer are an important intermediate between experiments
with transplanted cancer in laboratory animals and clinical
application in human cancer cases. If therapeutic eVects are
positive in well-performed, well-interpreted experiments
with transplanted cancer in laboratory animals as well as in
spontaneous cancer in veterinary patients, then one can be
almost certain that such a therapy will also be eVective in
human cancer patients.
Data
Table 3 summarizes all published studies that we know on
local IL-2 application in veterinary cancer patients.
Bovine Ocular Squamous Cell Carcinoma (BOSCC)
BOSCC originates in the cornea, the third eyelid (mem-
brana nictitans), the lower or the upper eyelid. Ultimately
the tumor covers the whole eye. It also metastasizes to the
draining lymph nodes. This tumor occurs frequently in
tropical countries with intense solar radiation, particularly
at high altitudes. BOSCC is for various reasons a very use-
ful veterinary tumor model: The tumor is readily visible
and can be directly treated with peritumoral or intratumoral
IL-2 injection in Weld studies.
In The Netherlands BOSCC is a very rare disease. So
our  Wrst tests of IL-2 sensitivity of BOSCC were per-
formed in only Wve cows with BOSCC [84]. The results
showed that BOSCC can be sensitive to local IL-2 therapy.
In Zimbabwe about 10% of the cows are aVected by
BOSCC. This allows large-scale studies [31]. Added to
this BOSCC causes an enormous economical burden.
In our most extensive study in Zimbabwe [86] we treated
174 BOSCC cases with tumor areas ranging from 20 to
2,800 mm2. Peritumoral injections of various doses of IL-2
were applied during 2 £ 5 days. Nine months after treat-
ment, the daily doses of 5 £ 103, 2 £ 104, 2 £ 105,
5 £ 105, 1 £ 106, 2 £ 106 U IL-2 had induced complete
tumor regression in 82, 81, 56, 15, 44, and 35% of the ani-
mals, respectively. In the control animals the tumors had
completely regressed in only 14% of the cases. After
20 months the comparable Wgures were 55, 52, 58, 50, 69
and 52%, respectively, and there had been no change in the
control group. The tumors on the third eyelid and limbus
were the most responsive [89]. Similar results were
obtained in other studies [30, 90].
Even large BOSCC tumors of up to 66 mm can regress
completely by local IL-2 therapy [31].
Bovine Vulval Papilloma and Carcinoma Complex 
(BVPCC)
BVPCC is a common disease in Bos taurus breeds of cat-
tle kept at high altitude with high levels of solar radiation
in Africa [19, 51]. It also occurs in other countries and
continents with similar high levels of solar radiation. Bur-
din [19] originally described the pathogenesis of this neo-
plasm. Hill et al. [51] adapted this description to develop
a useful system for clinical staging of the tumors. In Zim-
babwe BVPCC occurs in about 10% of the cattle. It
causes much animal suVering. In addition BVPCC usually
proceeds to a more advanced stage. So BVPCC forms a
real economical burden for the farmer and on a national
scale.
Twenty three papillomas and carcinomas of the bovine
vulva were treated with local IL-2 therapy. Sixteen partial
remissions and three complete remissions add to a tumor
Table 3 Therapeutic eVect of local IL-2 application veterinary cancer
patients
This Table summarizes to our knowledge all published studies on local
application of free IL-2 in veterinary cancer patients
+ Detectable eVect
++ Many CR cases
Type of cancer Host Therapeutic 
eVect
References
Bovine ocular squamous 
cell carcinoma
Cattle ++ [30, 31, 84, 89, 90]
Vulval papilloma and 
carcinoma complex
Cattle + [51]
Sarcoids Horses + [88]
Fibrosarcoma Dogs + [100]Cancer Immunol Immunother (2008) 57:931–950 937
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reduction in 83% of the treated cows [Stewart et al. to be
published]. Remissions were striking in papillomas with a
massive lymphocytic inWltrate in particular in those epithe-
lial areas that showed marked dysplasia or (pre-)malignant
changes.
Sarcoids
Sarcoids are Wbro-epithelial skin tumors of horses, don-
keys, and mules. InWltrative growth is prominent but they
seldom metastasize. After surgical removal they usually
recur. Sarcoids were treated by intratumoral IL-2 injections
for 5 or 10 days. There were 36 and 50% objective
responses, respectively after 12 months [88].
Fibrosarcomas in dogs
Tumors often occur in cats and dogs as owners care for
pets even into advanced age as members of the family.
Like ageing humans they show a large variety of tumors
in their later years. Preliminary data demonstrated that
Wbrosarcomas in dogs are sensitive to local IL-2 therapy
[100].
Conclusion
Local IL-2 therapy can be eVective against spontaneous
veterinary tumors. Local IL-2 application has an enormous
economical impact as BOSCC as well as BVPCC occur in
about 10% of cattle in Zimbabwe and probably also in other
tropical countries. Local IL-2 treatment of BOSCC leads to
CR in the majority of the cases, and led to tumor reduction
in the majority of BVPCC cases.
For ethical reasons speciWc immunity cannot be tested
in veterinary patients. However speciWcity and systemic
eVects have been shown in mice [68] and rabbits [96]
with transplanted tumors. EVective local IL-2 treatment
greatly improves the quality of life by reducing suVering.
These therapeutic eVects in veterinary cancer patients
make a strong case for the development and acceptance
of local IL-2 therapy with free IL-2 in human cancer
patients.
Results of local IL-2 tumor treatment in human cancer 
patients (Table 4)
Subject
The Wnal step in the experimental chain is the local applica-
tion of free IL-2 to human cancer. Many research groups




Kaplan et al. [59] treated basal carcinoma of the skin. A
total of 12 tumors were treated in eight patients. Overall
response rates were : complete response in 8 of 12 treated
tumors, partial response in 3 out of 12 treated tumors, stable
disease with no improvement in one tumor site.
Bladder carcinoma
Pizza et al. [79] obtained tumor regressions after intrale-
sional injections of IL-2 in bladder cancer. Repeated injec-
tions of IL-2 under cystoscopic control resulted in complete
regression of the tumor in three out of six patients and in
partial regression of another three patients.
Huland and Huland [53] obtained histologically con-
Wrmed complete remission lasting more than 6 months in
one out of Wve patients with urinary bladder carcinoma
after continuous IL-2 perfusion of the bladder for 5 days.
Gomella et al. [44, 45] treated 14 patients with super-
Wcial bladder carcinoma. Patients were treated Wrst with
transurethral resection leaving a marker lesion, followed by
Table 4 Therapeutic eVect of local IL-2 application on human cancer
patients
CR complete regression, PR partial regression, SD stable disease,
PD progressive disease
Type of cancer Number 
of patients
CR PR SD PD References
Basal cell carcinoma 12 8 3 1 – [59]
Bladder carcinoma 6 3 3 – – [79]
Bladder carcinoma 5 1 – 4 – [53]
Bladder carcinoma 14 3 – 11 – [44, 45]
Bladder carcinoma 9 9 – – – [41]
Bladder carcinoma 10 8 – 2 – [29]
Gastro-intestinal cancer 16 – 6 – 10 [61]
Hepatocellular carcinoma 5 – 1 3 1 [85]
Lung cancer; 
pleural eVusions
2 1 76–8 [ 71]
Melanoma 26 5 8 5 8 [35]
Melanoma 23 15 5 – 3 [80]
Mesothelioma 21 – 4 7 10 [43]
Mesothelioma 22 1 11 3 7 [5]
Mesothelioma 31 1 6 10 14 [22]
Mesothelioma 1 1 – – – [62]
Ovarian carcinoma 35 6 3 7 19 [34]
Ovarian carcinoma 17 6 3 – 8 [91]
Neoplastic eVusions 14 4 6 – 4 [65]
Total numbers 288 78 65 53 92
Percentage (%) 100 27 23 18 32938 Cancer Immunol Immunother (2008) 57:931–950
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intravesical IL-2 instillation. There were three complete
responses, one lasting more than 9 months.
Ferlazzo et al. [40, 41] treated superWcial bladder cancer
cases with intravesical infusions of IL-2. This gave similar
clinical results as obtained by vesical instillation with BCG
after transurethral resection.
Den Otter et al. [26,  29] treated patients with recurrent
bladder carcinoma stage T1, grades 1 to 2 with incomplete
transurethral resection leaving a marker tumor of 0.5–1.0 cm.
Two days after resection IL-2 was instilled for 2 h. Patients
were asked to turn over regularly in order to ensure maximal
exposure of IL-2 to the bladder wall. This procedure was
repeated on Wve consecutive days. Two months later the eVect
was measured by cystoscopy examination. In eight out of ten
patients the marker tumor had regressed completely. Four
patients were still tumor free after 30 to 54 months. In one
patient with a 7-years’ history of bladder cancer requiring 23
cystoscopies, the marker had only partially regressed after
2 months. After removal of the remainder of the marker this
patient was tumor free during the follow-up of 54 months.
Also, a patient with an 11 years’ history of recurrent bladder
cancer remained tumor free during the whole follow-up
period [29]. The Wnding that these patients remained tumor
free for >54 months suggests that these patients were (locally)
immune to the tumor after tumor regression.
Grasso et al. [47] treated 27 patients with transitional
bladder carcinoma Ta/T1-G1–2 with intravesical instilla-
tions of IL-2 for 1 h during 5 days. After 2 months none of
the lesions had disappeared or were clearly reduced. This
result seems to contrast with the Wndings by Den Otter et al.
[26, 29]. The diVerent treatment protocols may be essential:
Den Otter et al. started with an incomplete TUR followed
by IL-2 instillations, whereas Grasso et al. did not perform
a TUR before IL-2 instillation. TUR causes tumor cell
damage, which may induce tumor immunity. Interestingly,
Grasso et al. obtained 33.3% relapses after a median fol-
low-up of 12 months; this contrasted to the restrospective
analysis in which the historical recurrence rate per year was
95%.
Gastrointestinal tumors
Shirai et al. [85] treated Wve patients with hepatocellular
carcinoma with intratumoral IL-2 injections. In two patients
32 and 57% tumor regression was observed.
Krastev et al. [61] treated patients with diVerent forms
of stage III and IV gastrointestinal malignancies (primary
or metastatic) for whom no further treatment options were
available. With locoregionally applied IL-2 a modest but
clinically worthwhile improvement was obtained in six out
of 16 patients; remarkably these six all belonged to the
group of seven patients that were treated with intratumoral
IL-2.
Melanoma
Radny et al. [80] treated patients with skin and soft-tissue
melanoma metastases with intralesional injection of IL-2. A
total of 24 patients with AJCC stage III or IV melanoma
and single or multiple skin and soft-tissue metastases were
included. IL-2 was administered intralesionally into all
cutaneous and soft-tissue metastases accessible from the
skin, 2–3 times weekly, over 1–57 weeks. Response evalu-
ation was conWned to the intralesionally treated tumors. CR
of the treated metastases was achieved in 15 patients, the
longest remission lasting 38 months to date. In Wve patients
a PR was achieved and in a further three PD (one patient
was not assessable). A total of 245 metastases were treated.
There was CR in 209 (85%), and PR in 21 (6%). The ther-
apy was generally well tolerated; the observed adverse
events were mainly of grade 1–2 severity.
Pfohler and coworkers [78] treated two patients with
multiple cutaneous metastases of malignant melanoma with
intra and perilesional application of interleukin-2 and
achieved complete regression of these metastases.
Mesothelioma
Goey et al. [43] treated patients with pleural mesothelioma
stage I-IIA with continuous daily intrapleural infusion of
IL-2. PR occurred in four out of 21 evaluable patients with a
median time to progression of 12 months (range 5–37). SD
occurred in seven patients with a median time to progression
of 5 months (range 2–7). There were no CRs. The median
overall survival time was 15.6 months (range 3.0–43).
Astoul et al. [5] treated 22 patients with malignant pleural
mesothelioma. The response rate was evaluated 36 days after
treatment. There were one CR, 11 PR, three SD, and seven
PD. The median survival time of responders diVered signiW-
cantly from that of the non-responders (28 versus 8 months).
Castagneto et al. [22] treated 31 consecutive patients with
unresectable malignant pleural mesothelioma with pleural
eVusion with intrapleural instillation of IL-2. In 90% of the
patients there was no further or minimal asymptomatic pleural
Xuid collection. Median overall survival was 15 months
whereas the expected survival range of patients with involve-
ment of the visceral pleura is 9–12 months.
Krastev et al. [62] treated a patient with a large abdomi-
nal mesothelioma with intratumoral IL-2 injections and
IL-2 instillation in the peritoneal cavity. The tumor regressed
completely; the patient was cured and is still healthy and
working 6 years after publication.
Neoplastic eVusions
Masotti et al. [71] treated neoplastic pleural eVusions in 21
patients with non-small cell lung cancer with intrapleuralCancer Immunol Immunother (2008) 57:931–950 939
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administration of IL-2. CR was obtained in seven patients
and PR in six patients.
Lissoni et al. [65] treated 14 patients with neoplastic
eVusions from a variety of solid tumors. There were four
CR and six PR with a median duration of 4 months.
Castagneto et al. [22] treated pleural eVusions of meso-
thelioma as described in the previous section.
Ovarian carcinoma
Edwards et al. [34] treated patients with ovarian carcinoma
with infusions of IL-2. Eligibility criteria included six or
more courses of prior platinum-based chemotherapy and lap-
arotomy-conWrmed persistent or recurrent ovarian cancer.
Among 35 assessable patients, there were six laparotomy-
conWrmed CRs and three PRs. The median survival time of
the cohort was 13.7 months and the overall 5-year survival
probability was 13.9%. For the nine patients who demon-
strated responses, the median survival time had not been
reached at the time of publication (range 27 to 90+ months).
Taylor et al. [91] treated patients with advanced ovarian
cancer with intraperitoneal IL-2. Nine out of 17 patients
showed an objective response.
Renal cell carcinoma (lung metastases)
Huland et al. [52] introduced IL-2 inhalation therapy for
lung metastases of renal cell carcinoma. Progressive pul-
monary metastases responded dramatically in 15% of the
patients for a median of 15.5 months and were stabilized in
55% of patients for a median of 6.6 months. The overall
median response duration was 9.6 months. Median survival
was 11.8 months; expected survival according to risk anal-
ysis was 5.3 months [52].
The PortugeseSpanish Inhaled IL-2 Group [36] studied
the eVect of inhaled IL-2 on pulmonary metastases of renal
cell carcinomas. They found 13.7% Objective Responses
(OR), a median progression free survival of 8.6 months and
an overall survival of 23 months.
QuantiWcation of therapeutic data
Therapeutic data of Table 4 were further analyzed regard-
ing CR, PR, SD, and PD. This analysis was possible in 288
cancer patients treated with locally applied IL-2. There
were 27% CR, 23% PR, 18% SD, and 32% PD. These data
may be too optimistic as positive results are published more
frequently than negative results.
Toxic eVect of local IL-2 application
Table 5 shows the toxic eVect of local IL-2 application
to cancer patients. There were 24 papers with an abstract
mentioning toxic side eVects. In 20 papers there were no or
minor side eVects, one paper [41] reports some side eVects,
and three papers [22, 34, 43] mention more serious side
eVects. The latter papers have in common that very high IL-2
doses (see Table 5) were used for intrapleural, intraperito-
neal or subcutaneous administration. In essence these massive
doses act in a pseudo-systemic manner. Much of these
massive doses of IL-2 will be absorbed and as a conse-
quence will give generalized eVects similar to systemic
treatment. Hence, toxicity mentioned in the latter three
papers form the exception to the rule that local IL-2 appli-
cation causes no or minimal side eVects. In reference [43]
side eVects are due to the very high daily doses of
36 £ 106IU IL-2, as this was a Phase I-IIA study with esca-
lating doses of IL-2. In this case IL-2 treatment may give
systemic toxicity complications. In paper [22] patients were
treated with repeated intrapleural instillations with 9 £ 106
IU twice weekly for 4 weeks; in addition, in non-progress-
ing patients 3 £ 106 IU IL-2 were administered s.c. thrice
weekly for up to 6 months. Obviously such high intrapleu-
ral doses are readily resorbed and reach the general circula-
tion. Hence the toxicity (grade 3 fever and grade 3 cardiac
toxicity) in 7/31 patients is not surprising. In paper [34]
dose-limiting toxicity was seen in patients treated with 7-days’
infusions with the maximum tolerated dose; obviously
there was toxicity per deWnition.
Dose–response
Figure 1 shows the total applied doses of IL-2 and the per-
centage of objective responses. Results suggest that (a)
good therapeutic results can be obtained with low doses of
IL-2 (103 to 105IU); (b) that there is no dose-response
eVect in the range of total dose of 106 up to 109 IU IL-2. Of
course, in this Wgure there are only a few data for diVerent
tumors treated slightly diVerent by diVerent groups. More
detailed analysis with homogeneous groups of mice with
transplanted SL2 lymphoma in DBA/2 mice showed a dose
response eVect in the dose range of 5,000–200,000 IU IL-2
given on Wve consecutive days [12]. It is not surprising that
this was not reproduced with the very heterogeneous data in
Fig. 1. Nevertheless these data of Fig. 1 are remarkable as
total doses of 106–109 IU of IL-2 can result in 20–100%
objective responses. We have analysed whether high and
low percentages of objective responses are obtained with
sensitive and non-sensitive tumor types, respectively. This
seems not to be the case as bladder carcinoma, mesotheli-
oma, and ovarian carcinoma were reported as sensitive
(>60% OR) as well as non-sensitive (<60% OR) (Table 4;
Fig. 1). Another hypothesis is oVered by the work of Jacobs
et al. [55]. He found that intratumoral IL-2 application is
more eVective than peritumoral IL-2 application. We there-
fore further analyzed whether the diVerent therapeutic940 Cancer Immunol Immunother (2008) 57:931–950
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eVects can be ascribed to diVerences in the localization of
IL-2 application. Also this was not the case. Another possi-
bility is that intratumoral IL-2 application leads to more
intratumoral edema formation/leakage causing hemody-
namic stagnation and additional tumor necrosis. This may
stimulate the antitumor response and consequently lead to
superior therapeutic eVects. Obviously this hypothesis is
diYcult to study in human cancer patients for logistical and
ethical reasons. A more simple explanation of the absence
of a dose-response eVect is that diVerent tumors have diVer-
ent sensitivity for local IL-2 therapy, e.g., due to diVerent
tumor associated antigenicity. Those that are well-respon-
sive can be cured by lower doses, those that are less respon-
sive are (automatically) treated with higher doses. Hence it
is impossible to evaluate dose-response eVects using diVer-
ent tumors.
Conclusions
– Local IL-2 therapy can be eVective against a variety of
human tumors.
– In some studies results suggest that metastases are cured
and that (systemic) immunity is obtained [29].
– There is no obvious dose–response with regard to thera-
peutic eVects.
– Good therapeutic eVects can be obtained with total doses
of 103 to 105 IU IL-2; these doses cause no or negligible
toxic eVects. High total IL-2 doses of 108 IU and higher
Table 5 Toxic eVects of local IL-2 application on human cancer patients
Toxicity as described in the abstracts of the papers mentioned in Table 4
a Toxicity data from Abstracts that did not contain information for Table 4
b Alternating continuous 7 day infusions followed by 7-day intervals
Reference  Toxic side eVects
[59] Local pain, swelling, erythema, in one patient Xuelike symptoms
[79] No early or late adverse clinical side eVects
[53] No evidence of side eVects
[44, 45] Toxicity from IL-2 given intravesically was minimal. One patient malaise for 24 h after each treatment. 
Two patients developed asymptomatic lower urinary tract infections
[41] 2/9 patients had hematuria after the end of treatment; one patient had fever (grade I), and seven patients had 
hypotension (grade I-II)
[29] No toxic eVects
[61] Negligible adverse eVects
[85] Abstract did not contain toxicity data
[71] Treatment of pleural eVusions of lung cancer was well tolerated
[35]S i d e  e Vects of treatment were minimal
[80] Therapy was generally well tolerated; the observed adverse events were mainly of grade 1–2 severity
[43] Intrapleural administration of IL-2 was associated with acceptable toxicity. Dose limiting toxicity was ob-
served at 36 £ 106 IU daily, and consisted of catheter infection, fever and Xue-like symptoms.
[5] Intrapleural administration of IL-2 was well tolerated
[22] Patients with malignant pleural mesothelioma received intrapleurally 9 £ 106 U IL-2 twice weekly for 
4 weeks. In non progressing patients 3 £ 106 U IL-2 were subcutaneously administered thrice weekly 
for up to 6 months. Toxicity (WHO criteria) with intrapleural IL-2 consisted of grade 3 fever in 6/31 pa-
tients and cardiac toxicity (failure) grade 3 in one patient.
[62] Abstract did not contain toxicity data
[34]S i g n i Wcant locoregional dose-limiting toxicity was seen with 7 day infusionsb (including bowel perfora-
tion) with 6 £ 105 IU/m2/day as the maximum tolerated dose, but catheter infection was the only signiW-
cant complication seen with 24 hrs infusions
[91] Abstract did not contain cytotoxicity data
[65] No important toxicity in 14 patients with neoplastic eVusions after intracavitary administration of IL-2
[36]a Inhaled IL-2: most common toxicities were cough (40% of cycles) and fatigue (7%). Grade 1 or 2 toxicities 
[40]a Locoregional perfusion of the bladder with IL-2 is safe
[52]a 116 patients. Toxicity associated with exclusive inhalation of IL-2 was local and consisted mainly of cough
[93]a Intravesical IL-2 instillation. No evidence of toxicity
[97]a Regionally administered IL-2 was well tolerated in patients with advanced squamous cell carcinoma of the 
head and neckCancer Immunol Immunother (2008) 57:931–950 941
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may exert toxic side eVects as are described in systemic
treatment.
Combined therapy modalities (Table 6)
Subject
Combination of various therapeutic modalities, like sur-
gery, irradiation, chemotherapy, hormone therapy, etc., are
standard in tumor treatment. For this reason several groups
have also used local IL-2 therapy with free IL-2 combined
with other treatment modalities.
Data
Surgery
Ziekman [100] described cases of incomplete surgical
removal of a tumor in veterinary patients, followed by
intra-operative local IL-2 application. This led to complete
tumor regression for instance in dogs with Wbrosarcomas.
Fig. 1 % Objective response 
versus total applied dose of IL-2. 
The data are derived from the 
abstracts of the papers men-
tioned in Table 4


















Table 6 Synergism of local IL-2 therapy with other therapeutic modalities
a Comparison of therapeutic eVect of combined therapy and therapy without IL-2
b Tumor residua left after ifosfamide treatment
c Cis-platinum/IL-2 vs IL-2 only
Therapy Tumor Host Therapeutic eVect References
Surgery
Fibrosarcoma Dog CR for 12 months vs no CRa [100]
Radiotherapy
Lymphoma Mouse 93% vs. 17% disease free survival; P < 0.0001a [38, 58]
Nasopharyngeal carcinoma  Man 63% vs 8% disease free 5-years’ survival a [55]
Cytokine therapy
Interleukin-1 Friend leukemia Mouse  Synergistic eVect with IL-2, 60% survival [10]
Chemotherapy
Cyclophosphamide Melanoma  Mouse 87–91 vs 67% curesa [86]
Cis-platinum Terato carcinoma Mouse 20 vs 0% cures; 50% survival at ca 50 vs ca 25 daysa [14]
Doxorubicin M109 adenocarcinoma Mouse Synergistic eVect with long term survivors [20]
Ifosfamide TC1 Mouse Substantial inhibition of tumor residuab [54]
Cis-platinum Sarcoids Horse 53% CR, 27% PR vs 10–18% CR, 10–18% PRc [77]
Imiquinod Melanoma metastases Man  40.7% OR [48]942 Cancer Immunol Immunother (2008) 57:931–950
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IL-2 instillation in the bladder to treat bladder tumors
seems only eVective after a preceeding TUR (see above).
Radiotherapy
Everse et al. [38] treated mice with s.c. growing tumors
with radiotherapy combined with IL-2 therapy. The com-
bined therapy was more eVective than radiotherapy or IL-2
therapy alone. Similar results were obtained by J:rgenliemk-
Schulz et al. [58].
Early nasopharyngeal carcinoma is not clinically appar-
ent and hence these tumors are often diagnosed in an
advanced stage. The standard treatment is irradiation, often
complemented with chemotherapy. In The Netherlands
usually WHO type 1 nasopharynx carcinoma occurs. Type
1 is very therapy resistant. That is, only about 10% of the
patients treated with irradiation have a 5 years’ tumor free
survival [55]. In this study tumors of 10 patients were irra-
diated daily for 7 weeks. In weeks 2, 4, and 6 the tumors
were (transnasally) injected with low doses of IL-2 from
Monday through Friday. The 5 years’ tumor free survival
was 63% [55].
Cytokine therapy
Belardelli et al. [10] described that combined treatment
with IL-1 beta and IL-2 produced a synergistic antitumor
eVect: 60% of mice injected with highly metastasized
Friend Leukemia Cells survived. T cells appeared to be
essential for IL-1/IL-2 therapy.
Chemotherapy
Enk et al. [35] treated melanoma patients with pulmonary
metastases with dacarbazine and concurrent inhalation of
IL-2. The patients’ condition previously had progressed on
chemotherapy, predominantly on dacarbazine based regi-
mens. Five of the 27 patients experienced a complete
pulmonary remission. Eight patients achieved a partial
pulmonary remission, and Wve patients experienced stabil-
ization of the disease. Four of the Wve patients with a com-
plete response and seven of the eight patients with a partial
response were previously treated with dacarbazine and
progressed. The complete responses all persisted during a
follow-up of 12 months, whereas patients with partial
responses or stable disease progressed when IL-2 was
discontinued.
Silagi et al. [86] found synergism between cyclophos-
phamide and IL-2 in the treatment of mice with sarcoma or
melanoma.
Bernsen et al. [14] treated mice bearing Murine Ovarian
Teratocarcinoma (MOT) with cis-platinum and IL-2. The
eVect of the combined treatment was greater than either
therapies alone.
Similarly in horses with sarcoids (a characteristic equine
Wbro-epithelial tumor of the skin) the therapeutic eVect of
cis-platin and local IL-2 was greater than the therapeutic
eVect of either therapies alone [88].
Indrova et al. [54] studied mice with HPV-16 associated
tumors. Peritumoral IL-2 administration could substantially
inhibit growth of tumor residua after chemotherapy with
cyclophosphamide or ifosfamide derivatives.
Cabanes et al. [20] treated mice bearing M109 pulmo-
nary adenocarcinoma with a combination of liposomal
doxorubicin and free IL-2. Both the tumor and the IL-2
application were i.v. or both were i.p. There were synergis-
tic eVects with long-term survivors.
Green et al. [48] treated melanoma cases with multiple
cutaneous and/or subcutaneous metastases. Metastases
were treated with imiquinod daily for 4 weeks before the
introduction of intralesional IL-2. This was injected up to
three times a week. 182 lesions in a total of 10 patients
were treated. A clinical response was seen in 50.5% of the
lesions with 40.7% being CR. Furthermore patients with
clinically responding cutaneous lesions experienced a
marked slowing of the appearance of new lesions. No cuta-
neous lesions that responded reappeared on cessation of the
treatment. Imiquimod alone is often suYcient to elicit a
response in purely cutaneous lesions. The addition of int-
ralesional IL-2 however greatly increased the response rate
in subcutaneous lesions, and in otherwise refractory cutane-
ous melanomas.
Conclusion
Combined therapy of locally applied IL-2 and surgery,
radiotherapy or chemotherapy may lead to a synergistic
therapeutic eVect. The durable complete responses of mela-
noma metastases in the lung after combined chemotherapy
and IL-2 suggested that the metastases were eradicated
[35].
Mechanism of tumor regression due to local IL-2 
application 
Original hypothesis on the mechanism of IL-2 in tumor 
destruction
The original hypothesis about the function of systemically
applied IL-2 in cancer therapy was that IL-2 induced
Leucocyte Activated Killer cells (LAK cells; [15, 81, 82].
LAK cells were thought to invade the tumor and to kill
tumor cells.The following data are incompatible with theCancer Immunol Immunother (2008) 57:931–950 943
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cytotoxic LAK-cell hypothesis or any kind of cytotoxic cell
hypothesis:
– Hardly any intravenously injected LAK-cell reaches the
tumor [9].
– In the DBA/2-SL2 lymphoma model it is impossible to
induce cytotoxic LAK cells [67].Yet IL-2 therapy is very
eVective in this model.
– No general correlation was established between in vitro
sensitivity to the cytolytic activity of LAK cells and the
antitumor eVects observed in vivo [10].
– Various types of leucocytes may dominate the tumor
inWltrate after IL-2 application: macrophages, T cells,
NK cells, NKT cells, plasma cells, neutrophilic, eosino-
philic cells etc., [70]. The assumption that all these
diVerent types of cytotoxic cells are directly induced by
IL-2 in diVerent tumors is too complex to be true. In con-
trast IL-2 should induce a similar mechanism against a
wide range of (sensitive) cancers.
– In addition, when SL2 lymphoma is growing both i.p.
and s.c., and if IL-2 is injected i.p. at day 10 after tumor
transplantation, then in about 50% of the cases the s.c.
tumor regresses completely at about day 17, this in spite
of the tumor containing only 0–2% leucocytes [70].
Furthermore, eVector/target cell ratios of cytotoxic T-cells
are usually very low (in the order of 1:50). It is very
unlikely that such a huge tumor is rejected by these few
leukocytes. So, cytotoxic cells are not the major cause of
tumor regression in this experiment [68].
As this hypothesis was at least at some points wanting to
explain the mechanism of the antitumor activity of IL-2, we
started to study the histopathology of IL-2 induced tumor
regression as study of the histopathology of the IL-2
induced reaction would be essential.
IL-2 induced histopathology in normal tissue [60]
The study of the histopathological events during IL-2-
induced tumor regression proved to be extremely diYcult.
The breakthrough came by serendipity. Professor Hennink
and his group at the Faculty of Pharmacy, Utrecht Univer-
sity, are developing slow release systems (microspheres),
among others for IL-2. To study the biocompatibility of
these microspheres, we injected microspheres loaded with
IL-2 subcutaneous in rats [60]. We discovered that the
microspheres could be stained with PAS and thus these
stained microspheres marked the IL-2 release site. This
possibility of a precise localisation of IL-2 was a great tool
to further analyse the function of the released IL-2. In a
series of sections obtained during the IL-2 induced process
we could trace a sequence of reactions. First a localized
edema developed, related to swelling of the endothelial
lining of the capillaries. After 3 days necrosis of the connective
tissue was observed in the center of this edematous area.
About a week later there were three zones around this
necrotic area. Near the necrotic border was a zone of mixed
inXammatory cells. The second zone was a large area of
edematous connective tissue. The outer zone showed angio-
genesis, a massive proliferation of macrophages around the
newly formed blood vessels and also an inXux of lympho-
cytes. About 3–5 week later these macrophages invaded the
necrotic material showing features of phagocytosis. Finally
also plasma cells and occasionally eosinophils appeared in
the peri-necrotic inXammatory area. The plasma cells indi-
cate the induction of an immune reaction.
In short two main phases could be ascertained in this
process:
– an almost immediate marked edema due to leakage of
the local blood vessels;
– a later and more complex reaction consisting of the
induction of angiogenesis, a macrophage reaction,
migration of the inWltrate into the seminecrotic tissue and
Wnally clearance of tissue in combination with granulom-
atous processes.
Next we again studied the histopathology of the mecha-
nism of tumor regression induced by free IL-2. Of course
the histopathological events after injection of IL-2 in or
around a tumor are far more complex than the histopathol-
ogical events after subcutaneous injection of IL-2 loaded
microspheres in normal tissue in rats. But the events after
injection of IL-2 at the site of tumors were similar to those
after injection of IL-2 loaded microspheres in normal tis-
sue. It is remarkable, however, that IL-2 induced tumor
regression may be fast, requiring only some days, or slow,
requiring several months, or intermediate. These diVer-
ences can be related to histopathological diVerences of the
tumor tissues. Before we describe these diVerences we
have to pay attention to some hemodynamic features in
tumors.
Some hemodynamic features in tumors
In tumors the interstitial Xuid pressure is higher in the
center of the tumor mass than in surrounding tissue due to
vessel leakage [98]. The increased vascular leakage in
tumors is explained as follows:
– The tumor vessels usually lack a continuous basal mem-
brane [26].
– Endothelial injury in ischemic tissue [49].
– Tumors have poor homeostatic control of the circulation
due to lack of smooth muscle and lack of innervation
[25].
This vascular leakage causes increase of interstitial
pressure. This pressure will cause vascular compression,944 Cancer Immunol Immunother (2008) 57:931–950
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particularly of the post-capillary venules. This leads to stag-
nation of the blood Xow and vascular distension of the pre-
stenotic vessels and sometimes thrombosis in smaller blood
vessels. Stagnation of blood causes necrosis, in particular in
the tumor center. A peripheral rim of vital tumor tissue
often survives as it is just outside the area of deWcient blood
circulation.
Local IL-2 application into/near the tumor appeared to
induce additional edema in and around the tumor, just as in
normal tissue. Increased edema exerts extra pressure that
causes further stagnation of the blood Xow and of the
lymph drainage. Obviously, this leads to tumor necrosis
and thrombosis within only a few days. This early edema is
illustrated with photographs [8, 24, 60, 64].
Fast tumor regression of well-vascularized tumors 
(Fig. 2) [8]
It is remarkable that IL-2 induced tumor regression is very
quick in the case of (very) fast growing tumors like SL2
lymphoma and P815 mastocytoma [67, 68]. Similarly, rela-
tively fast growing cases of mammary carcinoma [73] or
BOSCC are more responsive to IL-2 than slower growing
BOSCC [91]. In fast growing tumors the intratumoral vas-
cular tree is relatively poorly developed and also the endo-
thelial lining of the microvessels is abnormal. Local IL-2
application will further stimulate vascular leakage. So we
assume that much Xuid will leak from the tumor vessels,
leading to edema, microthrombosis and extensive hemor-
rhages in the tumor. It is noteworthy that soon after IL-2
injection the tumor becomes Wrmer, indicating swelling of
the tumor mass by edema. This leads to extensive necrosis.
Of course, this large necrotic tumor mass will induce an
acute clearance reaction to remove this necrotic debris,
which causes an early reduction in size of the tumor mass.
This induces a marked immune reaction. It is also notewor-
thy that this tumor necrosis is accompanied by marked
angiogenesis. Adjacent to many of the newly formed
smaller blood vessels there is a cuV of proliferating macro-
phages, which ultimately move into the necrotic debris. As
diVerent tumors diVer in tumor associated antigen make-up,
they will induce also diVerent types of immune reactions,
dominated by macrophages, T cells, plasma cells, or eosin-
ophilic cells. This phenomenon can be observed in biopsies
taken late at the margin of the disappearing tumor. As a
result of the increased tumor immunity isolated tumor
strands may be enveloped by granulomatous inXammatory
tissue destroying tumor cells. SpeciWc antitumor immunity
induced by IL-2 has been described by Maas et al. [67, 68].
After an animal is cured, a second implant of the same
tumor is rejected [6, 68, 96].
Our present hypothesis (Fig. 2) seems now most
straightforward to explain the fast tumor regression induced
by IL-2 in fast growing tumors: The primary function of
locally applied IL-2 is the induction of vascular leakage.
This leads to an acute massive tumor necrosis and clearance
of necrotic tumor material. As a consequence of massive
liberation of antigenic tumor material an immune reaction
develops. The diVerent types of dominant cytotoxic cells
(CTL, eosinophils, macrophages etc.,) depend on the char-
acter of the tumor-associated antigens released in the
necrotic tumor debris.
According to this view, maximal therapeutic results will
be obtained with maximal edema formation within the
tumor. In line with this view is the Wnding that IL-2 is more
eVective when injected directly into the tumor than when
injected peritumorally [56].
It is interesting that it was originally thought that IL-2
killed tumor cells through induction of cytotoxic LAK cells
and that the vascular leakage seemed a nasty side eVect [7].
According to our present views, it is just the other way
round: vascular leakage causing edema is the primary eVect
of IL-2; the development of systemic immunity [68, 96]
seems the secondary eVect.
An intriguing point was for many years that in the DBA/
2-SL2 model local IL-2 therapy is not eVective 1–10 days
Fig. 2 Mechanism of tumor 
regression caused by local IL-2 
application of cancer
necrosis and apoptosis immunity
ca 90% of tumour 
cells die due to lack 
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after tumor cell transplantation, whereas it can be eVective
after 10 days until about 2 days before the expected death
[37, 67]. Similarly, Maekawa et al. [69] found that local IL-
2 therapy was only eVective when IL-2 therapy was given
seven or more days after transplantation of myeloma
X5563. This can be explained by the observation that these
days are required for developing a corona of angiogenesis
around the tumor; this is essential for an eVective local IL-2
therapy.
Slow tumor regression of less vascularized tumors
A number of tumors show a slow IL-2 induced regression.
Examples are BOSCC [30, 84] and sarcoids in the skin of
horses [88]. This regression pattern more closely follows
the histological changes as observed in the model, in which
the IL-2-releasing microspheres were deposited in normal
subcutaneous tissue [60]. Also in these slowly growing
tumors edema will be induced in the tumor, but this is more
focal at the site of the injection and does not involve the
entire tumor. Also the necrotic focus develops slower and
the necrosis is less hemorrhagic. In these tumors the com-
plete development of the IL-2 induced response takes at
least some weeks. So, the tumor immunity will develop
slower and consequently tumor regression will be slower.
Moreover in BOSCC the tumor contains only about 50%
of tumor cells; the other 50% is stroma. When a the tumor
is reduced in size by 50%, then usually hardly any or no
tumor cell is present anymore; the remaining 50% is stroma.
After killing of the tumor cells, the Wnal regression of
the stroma requires several additional months.
Of course both processes (edema and leukocyte inWltra-
tion after neoangiogenesis) are always present as a result of
local IL-2 application. But in fast-regression models edema
is more prevailing, in slow-regression models leukocyte
and particularly macrophage inWltration dominate.
Solid subcutaneous SL2 tumors expand by inWltrating
the surrounding tissue. These tumor strands are the Wrst tar-
gets of macrophages, as the tumor strands are in close prox-
imity to surrounding tumor stroma and are progressively
destroyed [8]. So, the body of the tumor and the inWltrating
tumor strands are destroyed in two diVerent ways, namely
by edema due to vascular leakage and a granulomatous
antitumor response originating in the tumor surrounding
stroma, respectively.
Obviously IL-2 may stimulate the existing inXammation
as often present in tumors and hence attracts more macro-
phages and inXammatory cells, and as a consequence inten-
siWes the already existing cellular response to the tumor.
Usually, there is in the perivascular zones a marked
increase of varied types of inXammatory cells.
The reduction of the tumor can be accelerated by using
IL-2 in combination with a tumor necrosis inducing agent,
as is demonstrated by local cis-platin treatment of mice
with MOT tumors [14] and sarcoids in horses [88]. Everse
et al. [38] showed that irradiation stimulated the therapeutic
eVect of IL-2 therapy in mice. We assume that the necrotic
material is phagocytosed, thus boosting an immune reac-
tion.
A remarkable Wnding is that IL-2 injected into the pri-
mary tumor can induce regression not only of the primary
tumor but also the metastasis in the draining lymph node [6,
96]. However, after surgical removal of the primary tumor
IL-2 cannot induce regression of the lymph node metastasis
[6]. We assume that this depends on the diVerences
between the histological structure of the primary tumors.
Usually in primary tumors there is extensive vasculariza-
tion and leucocyte inWltration and the tumor is in close con-
tact with the surrounding stroma. In contrast, early tumors
in lymphatic tissue often have a scanty vascularization and
are situated within the lymph nodes without a direct stroma
contact.
Tumor tolerance and local IL-2
In the previous sections histopathological techniques were
used to study the mechanism of IL-2 induced tumor regres-
sion. In this section we will also pay some attention to
immunological data.
Besides stimulating immune responses, IL-2 may also
inhibit immune responses. This is clear as deWciency of IL-
2 leads to autoimmunity[1]. IL-2 inhibits the immune
response by stimulation of CD4+CD25+ T regulatory cells
(Treg). These cells suppress immune reactivity including
antitumor immune responses [3, 75]. The presence of anti-
gen [77] and IL-2 are important in the maintenance of
CD4+CD25+ regulatory T lymphocytes. Depletion of
CD4+CD25+ Treg is important for tumor rejection [99].
Depletion of Treg with anti-CD25 antibody stimulates
tumor rejection [76].
Because of this tolerance inducing role of IL-2 through
Treg, some authors have suggested to use IL-15 for cancer
immunotherapy. IL-15 is a cytokine that is functionally
closely related to IL-2, but it does not induce tolerance [74].
In 1995, the Wrst animal studies for anti-cancer therapy
were performed with IL-15. Although IL-15 therapy still
lacks therapeutic successes in human clinic, some authors
still suggest that IL-15 should replace IL-2 for immunother-
apy of cancer [3].
Importantly and in contrast to IL-15, IL-2 is capable of
breaking tolerance [4, 11, 39, 70]. This may be crucial for
eVective anti-cancer immunotherapy. This reversal of toler-
ance is mediated through the activation of immature den-
dritic cells [63]. Activation of intratumoral dendritic cells
and reversal of tolerance exerted through local regulatory
CD4+CD25+ T lymphocytes, could be the link between946 Cancer Immunol Immunother (2008) 57:931–950
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local eVects of intratumoral IL-2 therapy and systemic
immunity. Stimulation of systemic immunity by local IL-2
therapy is also suggested by clinical data on cytokines in
treated human patients. Pro-inXammatory cytokines (IFN-
gamma, IL-5) are more increased after local IL-2 therapy
than anti-inXammatory cytokines. In contrast, anti-inXam-
matory cytokines (IL-10) are increased after systemic IL-2
therapy [92]. These data highlight mechanistic diVerences
between local and systemic IL-2 therapy.
The discussion above may lead to the question, whether
the speciWc immune system is involved in IL-2 induced
tumor rejection. Pleiotropic eVects of high local concentra-
tions of IL-2 could lead to aspeciWc activation of T cells,
activation of NK cells and the generation of LAK cells.
Nevertheless, the immune system must be involved as local
IL-2 treatment causes systemic immunity, that resides in
CD3+ lymphocytes or CD4+ and CD8+ lymphocytes
[69, 70].
Conclusions
Local IL-2 application seems to induce severe vascular
leakage in well-vascularized and fast growing tumors.
This leakage in fast growing tumors induces a massive
hemorrhagic necrosis which results in early clearance of
the tumor tissue. In less-vascular tumor tissue the edema
formation is more limited. Neoangiogenesis allows the
arrival of especially macrophages that move to the tumor
site. This leads to tumor cell killing and a speciWc
immune reaction, resulting in tumor regression. The
character of this immune reaction probably depends on
the diVerent types of tumor-associated antigens present
in the seminecrotic tumor debris. According to our views
the primary eVects of local IL-2 application to a tumor
are the vascular phenomena followed by a host of com-
plex histological events clearing the tumor necrosis. The
immune reactivity seems to be a secondary and presum-
ably an indirect eVect.
Of course, this is an analysis at the histopathological
level. The whole process is far more complicated as
immune regulatory events––including cells and cytokines
are involved.
Characteristics of local IL-2 therapy
– Local IL-2 treatment of cancer often cures also the
metastases [67, 68, 96]
– This systemic eVect is probably the result of IL-2
induced systemic immunity [67, 68].
– Local IL-2 therapy can cure large local tumors [31, 67,
68, 88] and even large metastasized tumor burdens [6,
67, 68, 96].
– Local IL-2 therapy is eVective against a large variety
of spontaneous carcinomas, melanoma, Wbrosarcoma,
equine sarcoid, mesothelioma, lung metastases of renal
cell carcinoma and melanoma (references see Tables 3,
4). Of course, local IL-2 application is no panacea for all
tumors and all types of cancer all the time.
– Intratumoral IL-2 application is more eVective than
peritumoral (juxtatumoral) application [55] or applica-
tion at a more distant site [68].
– A single IL-2 application may be suYcient [28]. This
can be advantageous during surgery when a tumor can-
not be excised completely.
– Local IL-2 therapy is particularly eVective in fast grow-
ing tumors [67, 68, 73, 91].
– Most of the tumors that well respond to local IL-2 treat-
ment are those with an already (pre-)existing peritumoral
leukocytic inWltrate.
– Local treatment of the primary tumor may result in
regression of both the primary tumor and a metastasis in
the draining regional lymph nodes [6, 96].
– IL-2 induced tumor regression can be fast [24, 67, 68],
but it is often a slow process requiring months [30, 31,
88]. The fast tumor regression is often observed in fast
growing highly vascularized tumors in which IL-2
causes vascular leakage, leading to edema and intravas-
cular thrombosis followed by necrosis. This is also a
consequence of the often abnormal endothelial lining of
the intratumoral vascular tree. Slow tumor regression
is often observed in poorly vascularized tumors with
prominent macrophage inWltration after IL-2 induced
neovascularization and an activation of the existing
round cell inWltrate. Prior induction of tumor necrosis
and local inXammation may accelerate the eVect of
IL-2.
– Local IL-2 therapy can exert a synergistic therapeutic
eVect with surgery, radiotherapy and chemotherapy (ref-
erences see Table 6). Thus local IL-2 treatment can be a
valuable addition to the standard oncotherapy.
– Local IL-2 has minor side eVects and is generally well
tolerated (references see Table 5). It can usually be
applied without diYculty. It does not require complex
technical procedures.
– Local IL-2 does not hamper or interfere with the stan-
dard oncotherapy.
The local IL-2 therapy Wndings suggest to revisit 
our views on the relation between local and systemic 
oncotherapy at least as far as IL-2 therapy concerns
Systemic chemotherapy/hormone therapy, and later immu-
notherapy, were initially particularly reserved for patients
in which adequate tumor treatment by surgery and radio-Cancer Immunol Immunother (2008) 57:931–950 947
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therapy was not possible. In most of these cases the tumor
was inoperable or disseminated and often the patient was in
the terminal phase of the disease. Now with modern thera-
peutic regimes the indications of systemic treatment have
been extended, whereas local tumor treatment is becoming
rare. Data described in this paper show that cancer treat-
ment with local IL-2 application can lead to cure of metas-
tases. We stress that there are good reasons to consider IL-2
tumor treatment also in early cancer.
Surgical treatment remains the golden standard in
malignant tumors. Local IL-2 therapy may be considered
in local tumors if these tumors can not be resected com-
pletely. Occasionally a previously inoperable lesion might
become Wt for surgical interventions due to the reduction
of the tumor size. In some cases local IL-2 application may
be considered as an adjunct to the standard treatment par-
ticularly if recurrences are expected. An example of the
latter is local IL-2 treatment in TUR-treated bladder
tumors.
Local IL-2 therapy may also be used as an adjunct to
treat a primary tumor showing metastases. In advanced
tumor cases local IL-2 treatment of the primary tumor
may induce a speciWc immune response and might also
contribute to cure or decrease tumor size and sometimes
also may have a positive eVect on the metastases. IL-2
does not interfere with the standard oncotherapy and
might be an useful adjunct to diminish suVering and
expand lifespan.
Dose at the tumor site Only about 0.1% of the systemi-
cally applied dose reaches the tumor. In other words the
same dose injected locally results at the site of the tumor in
a 1,000 times higher concentration than a systemically
applied dose.
Reduced side eVects An advantage of local treatment is
furthermore that side eVects, both local and systemic, are
modest if present at all, since the required local dose is only
a fraction of the dose required in systemic treatment.
No immunologic overXow feed-back Systemic IL-2 ther-
apy causes immuno suppression as indicated by systemic
IL-10 production. This is probably the body’s reaction to a
generally activated immune system (cytokine storm). Local
IL-2 avoids this down-regulating feedback, and leads to
systemic increase of pro-inXammatory cytokines, like IFN-
gamma and IL-5.
Reduced costs of locally applied low doses Systemic
chemotherapy and immunotherapy in cows and horses is no
option. Cattle and horses are so large that systemic onco-
therapy is out of order; e.g., required doses of IL-2 would
be very large and hence far too expensive in animal hus-
bandry. This problem can be circumvented by local ther-
apy. The results in cattle and horses show that local IL-2
therapy in these large animals is feasible, readily to apply,
economic, and therapeutically eVective.
Local IL-2 application: doses and duration 
of the treatment
The number of IL-2 injections required for optimal treatment
is still a point of debate. A single injection containing 2 up to
16 million U IL-2 is suYcient in the DBA/2–SL2 model
[28], whereas doses of only 5,000 U IL-2 were required in
case daily injections on Wve consecutive days were given
[67]. However, Kusnierczyk et al. [64] cured C57BL mice
with s.c. solid colon carcinoma with multiple IL-2 treat-
ments, whereas no cure was obtained by a single IL-2 injec-
tion. Treating spontaneous BOSCC with a single dose of
2 million U IL-2 [28] gave comparable results as daily IL-2
injection of the same dose on ten consecutive working days
[30]. For logistic reasons most clinicians (both in human and
in veterinary medicine) strongly prefer to apply one single
dose instead of daily injections over Wve or ten consecutive
working days. A single large dose can also be appropriate for
tumor treatment during surgery when the tumor mass cannot
completely be removed. But such a single dose should be
much higher (about 4.5 £ 106IU IL-2) than doses on Wve or
ten consecutive working days (ca 5,000 IU per day in mice).
Very diVerent IL-2 doses, time schedules and routes of
application were used. In a human patient we might con-
sider <106U IL-2 as low dose, (1–18) £ 106 U as interme-
diate dose, and >18 £ 106U IL-2 high dose for local IL-2
application. But a systemically applied dose is far more
toxic than the same dose after local application. In addition,
the same dose given i.p. in a mouse can be regarded to be
high, whereas this dose is low when it is given intrave-
nously in a human patient. A systemically applied dose of
106U IL-2 is intermediate. But if this dose is given daily for
100 days, then it is a large total dose.
Nowadays we usually treat cancer with a single local
injection of 4.5 £ 106U IL-2. This dose is based on data
obtained in mice, cattle and dogs [28]. It may be astounding
that in local treatment the same dose is eVective in a mouse
as well as in cattle. In fact similar local processes have to be
induced in these diVerent species. In systemic application
however the dose required by a cow has to be about 20,000
fold of that used in mice.
We preferably inject IL-2 inside the tumor. This leads to
better therapeutic results than peritumoral IL-2 application
[56].
Website
Our website on local IL-2 therapy is available at http://
cancerimmunotherapy.net/
We provide information targeted on medical profession-
als. Readers are invited to co-operation. Please reach us at
w.denotter@uu.nl.948 Cancer Immunol Immunother (2008) 57:931–950
123
Acknowledgments These studies were supported by the K.F. Hein
Fonds, Utrecht and by Chiron/Novartis. The cartoon was drawn by
Anne-Marie Keegstra.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
1. Altman A, TheoWlopoulos AN, Weiner R, Katz DH, Dixon FJ
(1981) Analysis of T cell function in autoimmune murine strains.
Defects in production and responsiveness to interleukin 2. J Exp
Med 154:791–808
2. Anderson PM, Katsanis E, Leonard AS, Schow D, LoeZer CM,
Goldstein MB, Ochoa AC (1990) Increased local antitumor
eVects of interleukin 2 liposomes in mice with MCA-106 sar-
coma pulmonary metastases. Cancer Res 50:1853–1856
3. Antoni PA, Restifo NP (2005) CD4+CD25+ T regulatory cells,
immunotherapy of cancer, and interleukin-2. J Immunother
28:120–128
4. Appleman LJ, Boussiotis VA (2003) T cell anergy and costimu-
lation. Immunol Rev 162:161–180
5. Astoul P, Picat-Joossen D, Viallat JR, Boutin C (1999) Intrapleu-
ral administration of interleukin-2 for the treatment of patients
with malignant pleural mesothelioma: a Phase II study. Cancer
86:546–547
6. Balemans LT, Steerenberg PA, Koppenhagen FJ, Kremer BH,
De Mulder PHM, Claessen AM, Scheper RJ, Den Otter W (1994)
PEG-IL-2 therapy of advanced cancer in the guinea pig. Impact
of the primary tumor and beneWcial eVect of cyclophosphamide.
Int J Cancer 58:871–876
7. Baluna R, Vitetta E (1997) Vascular leak syndrome: a side eVect
of immunotherapy. Immunopharmacology 37:117–132
8. Baselmans AHC, Koten JW, Battermann JJ, Van Dijk JE, Den
Otter W (2002) The mechanism of regression of solid SL2 lym-
phosarcoma after local IL-2 therapy. Cancer Immunol Immun-
other 51:492–498
9. Basse PH (1995) Tissue distribution and tumor localisation of
eVector cells in adoptive immunotherapy of cancer. APMIS
Suppl 55:1–28
10. Belardelli F, Ciolli V, Testa U, Montesoro E, Bulgarini D, Proi-
etti E, Borghi P, Sestili P, Locardi P, Peschle C, et al. (1989)
Anti-tumor eVect of interleukin-2 and interleukin-1 in mice trans-
planted with diVerent syngeneic tumors. Int J Cancer 44:1108–
1116
11. Bendiksen S, Rekvig OP (2004) Interleukin-2, but not interleu-
kin-15, is required to terminate experimentally induced clonal
T-cell anergy. Scand J Immunol 60:64–73
12. Bernsen MR, Dullens HFJ, Den Otter W, Heinz APM (1995) Re-
evaluation of the superiority of polyethylene glycol modiWed
Interleukin-2 over regular recombinant IL-2. J Interferon and
Cytokine Res 15:641–645
13. Bernsen MR, Tang J-W, Everse LA, Koten JW, Den Otter W
(1999) Interleukin-2 (IL-2) therapy: potential advantages of loco-
regional versus systemic administration. Cancer Treatment Rev
25:73–82
14. Bernsen MR, Van der Velden AW, Everse LA, Dullens HFJ, Den
Otter W, Heinz APM (1998) Interleukin-2: Hope in cases of Cis-
platin resistant tumours. Cancer Immunol Immunother 6:41–47
15. Bubenik J, Indrova M (1987) The anti-tumour eYcacy of human
recombinant interleukin 2. Correlation between sensitivity of
tumours to the cytolytic eVect of LAK cells in vitro and their
susceptibility to interleukin 2 immunotherapy in vivo. Cancer
Immunol Immunother 24:269–271
16. Bubenik J, Indrova M, Perlmann P, Berzins K, Mach O, Kraml J,
Toulcova A (1985) Tumour-inhibitory eVects of TCGF (IL-2)-
containing preparations. Cancer Immunol Immunother 9:57–61
17. Bubenik J, Kieler J, Indrova M (1986) Local treatment with hu-
man recombinant IL-2 inhibits growth of MC-induced sarcomas
in syngeneic mice. Folia Biol (Praha) 32:209–211
18. Bubenik J, Perlmann P, Indrova M, Simova J, Jandlova T,
Neuwirt J (1983) Growth inhibition of an MC-induced mouse
sarcoma by TCGF (IL-2) containing preparations. Cancer Immunol
Immunother 14:205–206
19. Burdin ML (1964) Squamous-cell carcinoma of the vulva in
cattle in Kenia. Res Vet Sci 4:497–505
20. Cabanes A, Even-Chen S, ZimberoV J, Barenholz Y, Kedar E,
Gabizon A (1999) Enhancement of antitumor activity of polyeth-
ylene glycol-coated liposomal doxorubicin with soluble and lipo-
somal interleukin-2. Clin Cancer Res 5:687–693
21. Casana PH, Hernandez H, Arana MJ (2002) Interleukin-2 inhib-
its proliferation of HPV-associated tumor cells and halts tumor
growth in vivo. Biochem Biophys Res Commun 299:818–824
22. Castagneto B, Zai S, Mutti L, Lazzaro A, RidolW R, Piccolini F,
Ardizzoni A, Fumagalli L, Valsuani G, Botta M (2001) Palliative
and therapeutic activity of IL-2 immunotherapy in unresectable
malignant pleural mesothelioma with pleural eVusion: results of
a phase II study on 31 consecutive patients. Lung Cancer 31:303–
310
23. Chi KH, Myers JN, Chow KC, Chan WK, Tsang YW, Chao Y,
Yen SH, Lotze MT (2001) Phase II trial of systemic recombinant
interleukin-2 in the treatment of refractory nasopharyngeal carci-
noma. Oncology 60:110–115
24. De Mik HJI, Koten JW, Maas RA, Dullens HFJ, Den Otter W
(1991) Tumour regression by IL-2 mediated stagnation of blood
Xow. In Vivo 5:679–684
25. Denekamp J (1984) Vascular endothelium as vulnerable element
in tumours. Acta Radiol Oncol 23:217–225
26. Den Otter W et al (1998) Letter. J Urol 160:1808
27. Den Otter W, Balemans L, Battermann JJ, 17 other authors
(1999) Local low-dose IL-2 therapy. Hepatogastroenterology
46(suppl.1):1280–1286
28. Den Otter W, Cadée J, Gavhumende R, De Groot CJ, Hennink
WE, Stewart R (1999) EVective cancer therapy with a single
injection of interleukin-2 at the site of the tumour. Cancer Immu-
nol Immunother 48:419–420
29. Den Otter W, Dobrowolski Z, Bugajski A, Papla B, Van der
Meijden APM, Koten JW, Boon TA, Siedlar M, Zembala M
(1998) Intravesical IL-2 to treat T1 papillary carcinoma : regres-
sion of marker lesions in 8 out of 10 patients. J Urol 159:1183–
1186
30. Den Otter W, Hill FWG, Klein WR, Koten JW, Steerenberg
PA, De Mulder PHM, Rhode C, Stewart R, Faber JAJ, Rutten
VPMG (1995) Therapy of bovine ocular squamous cell
carcinoma with local doses of Interleukin-2 : 67% complete
regressions after 20 months of follow-up. Cancer Immunol
Immunother 41:10–14
31. Den Otter W, Hill FWG, Klein WR, Koten JW, Steerenberg PA,
De Mulder PHM, Rutten VPMG, Ruitenberg EJ (1993) Low dos-
es of interleukin-2 can cure large bovine ocular squamous cell
carcinoma. Anticancer Res 13:2453–2455
32. Den Otter W, Steerenberg PA, Van der Laan JW (2002) Testing
therapeutic potency of anticancer drugs in animal studies: a com-
mentary. Regul Toxicol Pharmacol 35:266–272
33. Dubinett SM, Patrone L, Tobias J, Cochran AJ, Wen DR,
McBride WH (1993) Intratumoral interleukin-2 immunotherapy:
activation of tumor-inWltrating and splenic lymphocytes in vivo.
Cancer Immunol Immunother 36:156–162Cancer Immunol Immunother (2008) 57:931–950 949
123
34. Edwards RP, Gooding W, Lembersky MC, Colonello K, Ham-
mond R, Paradise C, Kowal CD, Kunschner AJ, Baldisser IM,
Kirkwood JM, Herberman RB (1997) Comparison of toxicity and
survival following intraperitoneal recombinant Interleukin-2 for
persistent ovarian cancer after platinum: twenty-four-hour versus
7-day infusion. J Clin Oncol 15:3399–3407
35. Enk AH, Nashan D, Rubben A, Knop J (2000) High dose inhala-
tion interleukin 2 therapy for lung metastases in patients with
malignant melanoma. Cancer 2042–2046
36. Esteban-González E, Carballido J, Navas V, Torregrosa Z,
Munoz A, de Mon MA, PortugueseSpanish Inhaled IL-2 Group
(2007) Prospective review in patients with pulmonary metastases
of renal cell carcinoma receiving inhaled recombinant interleu-
kin-2. Anticancer Drugs 18:291–296
37. Everse LA, Bernsen MR, Dullens HFJ, Den Otter W (1996)
The success of locoregional low-dose recombinant interleukin-2
(rIL-2) therapy in tumor-bearing mice is dependent on the time of
rIL-2 administration. J Exp Ther Oncol 1:231–236
38. Everse LA, Renes B, Jürgenliemk-Schulz IM, Rutgers DH,
Bernsen MR, Dullens HFJ, Den Otter W, Battermann JJ (1997)
Local low-dose interleukin-2 induces systemic immunity when
combined with radiotherapy of cancer. A pre-clinical study. Int J
Cancer 72:1003–1007
39. Fasler S, Aversa G, Terr A, Thestrup-Pedersen K, de Vries JE,
Yssel H (1995) Peptide-induced anergy in allergen-speciWc
human Th2 cells results in lack of cytokine production and B cell
help for IgE synthesis. Reversal by IL-2, not by IL-4 or IL-13.
J Immunol 155:4199–4206
40. Ferlazzo G, Magno C, Iemmo R, Rizzo M, Lupo G, Semino C,
Bruno S, Melioli G (1996) Treatment of superWcial bladder
cancer with intravesical perfusion of rIL-2: a follow-up study.
Anticancer Res 16:979–980
41. Ferlazzo G, Magno C, Lupo G, Rizzo M, Iemmo R, Semino C,
Melioli G (1995) A phase I study of intravesical continuous per-
fusion of recombinant interleukin-2 in patients with superWcial
bladder cancer. Am J Clin Oncol 16:100–104
42. Fiszer-Maliszewska L, Den Otter W, Mordarski M (1999) EVect of
local interleukin-2 treatment on spontaneous tumours of diVerent
immunogenic strength. Cancer Immunol Immunother 47:306–314
43. Goey SH, Eggermont AM, Punt CJ, Slingerland R, Gratama JW,
Oosterom R, Oskam R, Bolhuis RL, Stoter G (1995) Intrapleural
administration of interleukin-2 in pleural mesothelioma: a phase
I-II study. Br J Cancer 72:1283–1288
44. Gomella LG, McGinnis DE (1998) Letter to the Editor. Urology
160:1808
45. Gomella LG, McGinnis DE, Baltish MA, Thompson I, Butler K,
Marshall E (1993) Treatment of superWcial transitional cell carci-
noma of the bladder with recombinant interleukin-2 (rIL-2) (CE-
TUS). Cancer Biother 8:223–227
46. Grande C, Firvida JL, Navas V, Casal J (2006) Interleukin-2 for
the treatment of solid tumors other than melanoma and renal cell
carcinoma. Anticancer Drugs 17:1–12
47. Grasso M, Torelli F, Scannapieco G, Franzoso F, Lania C (2001)
Neoadiuvant treatment with intravesical Interleukin-2 for
recurrent superWcial transitional bladder carcinoma Ta-T1/G1–2.
J Immunother 24:184–187
48. Green DS, Bodman-Smith MD, Dalgleish AG, Fischer MD
(2007) Phase I/II study of topical imiquinod and intralesional
interleukin-2 in the treatment of accessible metastases in malig-
nant melanoma. Br J Dermatol 156:337–345
49. Gregoriadis G, Poste G (1984) Drug targeting in cancer therapy.
In: Senior J, Trouet A (eds), Receptor-mediated targeting of
drugs. Plenum Press, New York, pp 448–451
50. Hautmann SH, Huland E, Huland H (1999) Local intratumor
immunotherapy of prostate cancer with interleukin-2 reduces
tumor growth. Anticancer Res 19:2661–2663
51. Hill FWG, Klein WR, Hoyer HJ, Rutten VPMG, Kock N, Steer-
enberg PA, Ruitenberg EJ, Den Otter W (1994) Antitumor eVect
of locally injected low doses of recombinant human interleukin-
2 in bovine vulval papilloma and carcinoma. Vet Immunol
Immunopathol 41:19–29
52. Huland E, Heinzer H, Mir TS, Huland H (1997) Inhaled inter-
leukin-2 therapy in pulmonary metastatic renal cell carcinoma.
Cancer J Sci Am 3(Suppl 1):S98-S105
53. Huland E, Huland H (1989) Local continuous high dose interleu-
kin 2: a new therapeutic model for the treatment of advanced
bladder carcinoma. Cancer Res 49:5469–5474
54. Indrova M, Bubenik J, Mikyskova R, Mendoza L, Simova J, Bie-
blova J, Jandlova T, Jinoch P, Smahel M, Vonka V, Pajtasz-
Piasecka E (2003) Chemoimmunotherapy in mice carrying
HPV16-associated, MHC class I+ and class I- tumours: EVects of
CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically
modiWed tumour vaccines. Int J Oncol 22:691–695
55. Jacobs JJL, Hordijk GJ, Jürgenliemk-Schulz IM, Terhaard CHJ,
Koten JW, Battermann JJ, Den Otter W (2005) Treatment of
stage III-IV nasopharyngeal carcinomas by external beam irradi-
ation and local low doses of IL-2. Cancer Immunol Immunother
54:792–798
56. Jacobs JJL, Sparendam D, Den Otter W (2005) Local interleukin-
2 therapy is therapeutically more eVective against cancer when in-
jected intratumourally. Cancer Immunol Immunother 54:647–654
57. Janssen RA, Mulder NH, The TH, de Leij L (1994) The immuno-
biological eVects of interleukin-2 in vivo. Review. Cancer Immu-
nol Immunother 39:207–216
58. Jürgenliemk-Schulz IM, Renes IB, Rutgers DH, Everse LA,
Bernsen MR, Den Otter W, Battermann JJ (1997) Anti-tumor
eVects of local irradiation in combination with peritumoral
administration of low doses of recombinant interleukin-2 (rIL-2).
Radiat Oncol Investig 5:54–61
59. Kaplan B, Moy RL (2000) EVect of perilesional injections of
PEG-interleukin-2 on basal cell carcinoma. Dermatol Surg
26:1037–1040
60. Koten JW, Van Luyn MJA, Cadée JA, Brouwer L, Hennink WE,
Bijleveld C, Den Otter W (2003) IL-2 loaded dextran micro-
spheres with attractive histocompatibility properties for local
IL-2 cancer therapy. Cytokine 24:57–66
61. Krastev Z, Koltchakov C, Tomova R, Deredjian S, Alexiev A,
Popov D, Tomov B, Koten JW, Jacobs J, Den Otter W (2005)
Locoregional IL-2 low dose application for gastrointestinal tumors.
World J Gastroenterol 11:5525–5529
62. Krastev Z, Koltchakov V, Vladov N, Popov D, Milev A, Koten
JW, Den Otter W (2001) A mesothelioma that is sensitive to
locally applied IL-2. Cancer Immunol Immunother 50:226–227
63. Kubo T, Hatton RD, Oliver J, Liu X, Elson CO, Weaver CT
(2004) Regulatory T cell suppression and anergy are diVeren-
tially regulated by proinXammatory cytokines produced by TLR-
activated dendritic cells. J Immunol 173:7249–7258
64. Kusnierczyk H, Pajtasz-Piasecka E, Koten JW, Bijleveld C,
Krawczyk K, Den Otter W (2004) Further development of local
IL-2 therapy of cancer: multiple versus single IL-2 treatment of
transplanted murine colon carcinoma. Cancer Immunol Immun-
other 53:445–452
65. Lissoni P, Barni S, Ardizzoia A, Paolorossi F, Tisi E, Crispino S,
Tancini G (1992) Intracavitary administration of interleukin-2 as
palliative therapy for neoplastic eVusions. Tumori 78:118–120
66. Liu CM, Suzuki Y, Chen LP, Okayasu T, Calkins CE, Wheelock
EF (1990) Maintenance and cure of the L5178Y murine tumor-
dormant state by interleukin-2: in vivo and in vitro eVects. Cancer
Res 50:1361–1367
67. Maas RA, Dullens HFJ, De Jong WH, Den Otter W (1989)
Immunotherapy of mice with a large burden of disseminated lym-
phoma with low-dose interleukin-2. Cancer Res 49:7037–7040950 Cancer Immunol Immunother (2008) 57:931–950
123
68. Maas RA, Van Weering DHJ, Dullens HFJ, Den Otter W (1991)
Intratumoral low-dose interleukin-2 induces rejection of distant
solid tumour. Cancer Immunol Immunother 33:389–394
69. Maekawa R, Matsumoto M, Kitagawa T, Harada M, Sato K
(1986) EVect of recombinant IL-2 (R-IL-2) on in vivo growth of
murine myeloma X5563. Cancer Immunol Immunother 23:25–
30
70. Margolin KA (2000) Interleukin-2 in the treatment of renal can-
cer. Semin Oncol 27:194–203
71. Masotti A, Fumagalli L, Morandini GC (1997) Intrapleural
administration of recombinant interleukin-2 in non-small cell
lung cancer with neoplastic pleural eVusion. Monaldi Arch Chest
Dis 52:225 228
72. Mattijssen V, Balemans LTM, Steerenberg PA, De Mulder PHM
(1992) Polyethylene-glycol-modiWed interleukin-2 is superior
to interleukin-2 in locoregional immunotherapy of established
guinea pig tumours. Int J Cancer 51:812–817
73. Moiseeva EV, Merkulova IB, Bijleveld C, Koten JW, Miroshni-
kov AI, Den Otter W (2003) Therapeutic eVect of a single dose
of IL-2 on transplanted murine breast cancer. Cancer Immunol
Immunother 52:487–496
74. Munger W, Dejoy SQ, Wick MM, Kerwar SS (1995) Studies on
evaluating the antitimour acticity and toxicity of interleukin-15,
a new T cell growth factor: comparison with interleukin-2. Cell
Immunol 165:289–293
75. Nelson BH (2004) IL-2 regulatory T cells, and tolerance. J Immu-
nol 172:3983–3988
76. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakay-
ama E (1999) Tumor rejection by in vivo administration of
anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.
Cancer Res 59:3129–3133
77. Onodera K, Volk HD, Ritter T, Kupiec-Weglinski JW (1998)
Thymus requirement and antigen dependency in the “Infectious”
tolerance pathway in transplant recipients. J Immunol 160:5765–
5772
78. Pfohler C, Steinhauser S, Wagner A, Ugurel S, Tilgen W (2004)
Complete remission of cutaneous satellite and in-transit metasta-
ses. After intralesional therapy with interleukin-2 in 2 patients
with malignant melanoma Hautarzt. 55:171–175 (Article in Ger-
man)
79. Pizza G, Severini G, Menniti D, De Vinci C, Corrado F (1984)
Tumour regression after intralesional injection of interleukin-2
(IL-2) in bladder cancer. Preliminary report. Int J Cancer 34:359–
367
80. Radny P, Caroli UM, Bauer J, Paul T, Schlegel C, Eigentler TK,
Weide B, Schwartz M, Garbe C (2003) Phase II trial of intrale-
sional therapy with interleukin-2 in soft tissue melanoma metas-
tases. Br J Cancer 89:1620–1626
81. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE,
Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT,
Seipp CA, Simpson C, Reichert CM (1985) Observations on the
systemic administration of autologous lymphokine activated
killer cells and recombinant IL-2 to patients with metastatic
cancer. New Engl J Med 313:1485–1492
82. Rosenberg SA, Mulé, Spiess PJ, Reichert CM, Schwarz SL
(1985) Regression of established pulmonary metastases and sub-
cutaneous tumor mediated by the systemic administration of
high-dose recombinant interleukin-2. J Exp Med 161:1169–1188
83. Rosenstein M, Ettinghausen SE, Rosenberg SA (1986) Extrava-
sation of intravascular Xuid mediated by the systemic administra-
tion of recombinant interleukin 2. J Immunol 137:1735–1742
84. Rutten VPMG, Klein WR, De Jong WAC, Misdorp W, DenOtter
W, Steerenberg PA, De Jong WH, Ruitenberg EJ (1989) Local
IL-2 therapy in bovine ocular squamous cell carcinoma. A pilot
study. Cancer Immunol Immunother 30:165–169
85. Shirai M, Watanabe S, Nishioka M (1990) Antitumour eVect of
intratumoral injection of human recombinant interleukin-2 in
patients with hepatocellular carcinoma: a preliminary report. Eur J
Cancer 26:1045–1048
86. Silagi S, Schaefer AE (1986) Successful immunotherapy of
mouse melanoma and sarcoma with recombinant interleukin-2
and cyclophosphamide. J Biol Resp Mod 5:411–422
87. Sosnovski JT, DeHaven JI, Riggs DR, Lamm DL (1991) Treat-
ment of murine transitional cell carcinoma with intralesional
interleukin-2 and murine interferon gamma. J Urol 146:1164–
1167
88. Spoormakers TJP, Klein WR, Jacobs JJL, Van den Ingh ThS-
GAM, Koten JW, Den Otter W (2003) Comparison of the local
treatment of equine sarcoids with IL-2 or cisplatin/IL-2. Cancer
Immunol Immunother 52:179–184
89. Stewart RJE, Hill FWG, Masztalerz A, Jacobs JJL, Koten JW,
Den Otter W (2006) Treatment of ocular squamous cell carcino-
mas in cattle using interleukin-2. Vet Rec 159:668–672
90. Stewart RJE, Masztalerz A, Jacobs JJL, Den Otter W (2005)
Local interleukin-2 and interleukin-12 therapy of bovine ocular
squamous cell carcinomas. Vet Immunol Immunopathol
106:277–284
91. Taylor DD, Edwards RP, Case CR, Gercel-Taylor C (2004) Mod-
ulation of CD3-zeta as a marker of clinical response to IL-2 ther-
apy in ovarian cancer patients. Gynecol Oncol 94:54–60
92. Tomova R, Pomakov J, Jacobs JJL, Adjarov D, Popova S,
Altankova I, Den Otter W, Krastev Z (2006) Changes in cytokine
proWle during local IL-2 therapy in cancer patients. Anticancer
Res 26:2037–2047
93. Tubaro A, Stoppacciaro A, Velotti F, Bossola PC, Cusumano G,
Vicentini C, De Carli P, Ruco L, Santoni A, Cancrini A, et al.
(1995) Local immunotherapy of superWcial bladder cancer by
intravesical instillation of recombinant interleukin 2. Eur Urol
28:297–303
94. Vaage J (1987) Local and systemic eVects during interleukin-2
therapy of mouse mammary tumors. Cancer Res 47:4296–4298
95. Vaage J (1991) Peri-tumor interleukin-2 causes systemic thera-
peutic eVect via interferon-gamma induction. Int J Cancer
49:598–600
96. Van Es R, Baselmans AHC, Koten JW, Van Dijk JE, Koole R,
Den Otter W (2000) Perilesional IL-2 treatment of a VX2 head
and neck cancer model can induce a systemic anti-tumour activ-
ity. Anticancer Res 20:4163–4170
97. Vlock DR, Snyderman CH, Johnson JT, Myers EN, Eibling DE,
Rubin JS, Kirkwood JM, Dutcher JP, Adams GL (1994) Phase Ib
trial of the eVect of peritumoral and intranodal injections of inter-
leukin-2 in patients with advanced squamous cell carcinoma of
the head and neck: an Eastern Cooperative Oncology Group trial.
J Imunother Emphasis Tumor Immunol 15:134–139
98. Wiig H (1982) Microvascular pressures in DMBA-induced rat
mammary tumors. Scand J Clin Lab Invest 42:165–171
99. Yu P, Lee Y, Liu W, Krausz T, Chong A, Schreiber H, Fu YX
(2005) Intratumor depletion of CD4+ cells unmasks tumor
immunogenicity leading to the rejection of late-stage tumors.
J Exp Med 201:779–791
100. Ziekman PGPM (1999) Local low-dose IL-2 therapy of tumours
in companion animals. Anticancer Res 19:1995